9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Intrapleural Gene Transfer for Pleural Mesothelioma

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 13 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: UPCC 18508; 808806|P01CA066726 Study First Received: September 29, 2010 Last Updated: September 21, 2015 Estimated Primary Completion Date: May 2015 Primary Outcome Measures: To analyze gene transfer with two does separated by three-day interval Sponsors and Collaborators: Abramson Cancer Center of the University of Pennsylvania|National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01212367...

Continue reading

PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery

Condition Advanced Malignant Mesothelioma|Epithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma Estimated Enrollment: 13 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: NCI-2012-02839|PHII 67|N01CM62209 Study First Received: August 16, 2006 Last Updated: December 17, 2014 Estimated Primary Completion Date: March 2009 Primary Outcome Measures: Objective Tumor Response Rate According to the Response Evaluation Criteria in Solid Tumors (RECIST) Committee|Overall Survival|Time to Progression|Toxicity Profile as Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0.|Apoptosis by TUNEL Assay|Histone Acetylation by IHC and Western Blotting Sponsors and Collaborators: National Cancer Institute (NCI) Result...

Continue reading

Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM) Patients

Condition MALIGNANT PLEURAL MESOTHELIOMA Estimated Enrollment: 121 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Cohort|Time Perspective: Retrospective Study ID Numbers: ONC/OSS-04/2008 Study First Received: March 23, 2009 Last Updated: December 1, 2014 Estimated Primary Completion Date: December 2011 Primary Outcome Measures: Evaluate the expression and allelic variants of a panel of candidate genes involved in the resistance to drugs, the genome wide copy number changes in patients treated with drugs combination in the first line|Evaluate retrospectively the correlation between gene expression and polymorphisms in candidate genes and array-CGH data, immunohistochemistry data, and clinical data. Sponsors and Collaborators: Istituto Clinico Humanitas Result Received: No...

Continue reading

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Condition Advanced Malignant Mesothelioma|Epithelial Mesothelioma|Localized Malignant Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma Estimated Enrollment: 51 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: NCI-2009-00126|N01CM17102|CDR0000463521|14203B Study First Received: March 29, 2006 Last Updated: July 25, 2014 Estimated Primary Completion Date: September 2010 Primary Outcome Measures: Objective Response Rate, Complete (CR) or Partial (PR) Response|Changes in Laboratory Correlates|Pharmacogenomics by Correlating Genetic Polymorphisms With Drug Activity and Toxicity Sponsors and Collaborators: National Cancer Institute (NCI) Result Received: July 1, 2013 Website Link: https://ClinicalTrials.gov/show/NCT00309946...

Continue reading

Gefitinib in Treating Patients With Malignant Mesothelioma

Condition Advanced Malignant Mesothelioma|Epithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma Estimated Enrollment: 40 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: NCI-2012-02414|CLB-30101|U10CA031946|CDR0000068938 Study First Received: October 11, 2001 Last Updated: January 15, 2013 Estimated Primary Completion Date: February 2006 Primary Outcome Measures: Percentage of patients who remain failure-free|Tumor response rate|Toxicities, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0|Overall survival|Failure-free survival within patient subgroups defined in terms of epidermal growth factor receptor (EGFR) overexpression and cyclooxygenase-2 (COX-2) expression Sponsors and Collaborators: National Cancer Institute (NCI) Result Received: No Study...

Continue reading

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung

Condition Advanced Malignant Mesothelioma|Epithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma Estimated Enrollment: 55 Age Group: Child, Adult, Senior Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: NCI-2012-02466|SWOG-S0218|U10CA032102|CDR0000069360 Study First Received: June 6, 2002 Last Updated: January 23, 2013 Estimated Primary Completion Date: June 2007 Primary Outcome Measures: Overall survival rate|RECIST response rate|Association between EGFR expression with survival and response Sponsors and Collaborators: National Cancer Institute (NCI) Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00039182...

Continue reading

S0509 – AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

Condition Advanced Malignant Mesothelioma|Epithelial Mesothelioma|Recurrent Malignant Mesothelioma|Sarcomatous Mesothelioma Estimated Enrollment: 54 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: NCI-2012-02902|S0509|U10CA032102|CDR0000446178 Study First Received: October 20, 2005 Last Updated: September 21, 2015 Estimated Primary Completion Date: April 2010 Primary Outcome Measures: Overall Response Rate|Overall Survival|Progression-free Survival|Disease Control Rate|Objective Response Rate Per Modified RECIST for Pleural Tumors|Adverse Event Rates|Adverse Events Sponsors and Collaborators: National Cancer Institute (NCI) Result Received: October 30, 2012 Website Link: https://ClinicalTrials.gov/show/NCT00243074...

Continue reading

Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma

Condition Malignant Mesothelioma|Metastatic Cancer Estimated Enrollment: 196 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: P00804|PAPWORTH-MESOVATS|PAPWORTH-P00804|EU-20901|ISRCTN34321019 Study First Received: January 13, 2009 Last Updated: June 27, 2013 Estimated Primary Completion Date: February 2013 Primary Outcome Measures: Survival at 1 year after treatment|Control of pleural effusion|Complications, including need for more surgery, persistent air leak requiring pleural intubation for > 10 days, and hospital stay for > 12 days|Symptoms and quality of life as assessed by the EuroQol questionnaire|Length of hospital stay|Exercise tolerance|Cost to the health service, in terms of resources used for...

Continue reading

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Condition Part A and B: Advanced Solid Malignancies|Part C: Malignant Mesothelioma Estimated Enrollment: 73 Age Group: 20 Years to 130 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Masking: No masking|Primary Purpose: Other Study ID Numbers: D4880C00010 Study First Received: May 14, 2014 Last Updated: April 12, 2017 Estimated Primary Completion Date: January 27, 2017 Primary Outcome Measures: Adverse event Sponsors and Collaborators: AstraZeneca Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02141347...

Continue reading

Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma

Condition Lung Cancer|Malignant Mesothelioma Estimated Enrollment: 20 Age Group: 20 Years to 70 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Primary Purpose: Treatment Study ID Numbers: CDR0000067177|RPCI-DS-96-25 Study First Received: November 1, 1999 Last Updated: March 3, 2011 Estimated Primary Completion Date: June 1998 Primary Outcome Measures: Sponsors and Collaborators: Roswell Park Cancer Institute Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00003974...

Continue reading